Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study

SIMPLE SUMMARY: This was a phase III randomized controlled trial investigating the outcomes of low-dose interleukin-2 (IL-2) plus interferon alfa (IFNα) versus sunitinib as the first line and axitinib as the second line in patients with low- and intermediate-risk metastatic renal cell carcinoma (mRC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadono, Yoshifumi, Konaka, Hiroyuki, Nohara, Takahiro, Izumi, Kouji, Anai, Satoshi, Fujimoto, Kiyohide, Koguchi, Tomoyuki, Ishibashi, Kei, Kawai, Noriyasu, Nakane, Keita, Iba, Akinori, Masumori, Naoya, Takahara, Shizuko, Mizokami, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216557/
https://www.ncbi.nlm.nih.gov/pubmed/37345082
http://dx.doi.org/10.3390/cancers15102745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216557/
https://www.ncbi.nlm.nih.gov/pubmed/37345082
http://dx.doi.org/10.3390/cancers15102745

Ejemplares similares